{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:45:03Z","timestamp":1794645903203,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.autrev.2022.103168","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T19:22:41Z","timestamp":1659813761000},"page":"103168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["JAK inhibitors and systemic sclerosis: A systematic review of the literature"],"prefix":"10.1016","volume":"21","author":[{"given":"Clothilde","family":"Moriana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moulinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.autrev.2022.103168_bb0005","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"issue":"3","key":"10.1016\/j.autrev.2022.103168_bb0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.autrev.2022.103168_bb0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"25","key":"10.1016\/j.autrev.2022.103168_bb0020","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2022.103168_bb0025","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.autrev.2022.103168_bb0030","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103168_bb0035","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103168_bb0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00281-015-0511-7","article-title":"Cytokines in the immunopathology of systemic sclerosis","volume":"37","author":"Raja","year":"2015","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103168_bb0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","article-title":"The immune pathogenesis of scleroderma: context is everything","volume":"15","author":"Greenblatt","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2022.103168_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103168_bb0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2022.103168_bb0060","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2022.103168_bb0065","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2022.103168_bb0070","article-title":"JAK1\/2 inhibitor Baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis","volume":"9","author":"Hou","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.autrev.2022.103168_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.55563\/clinexprheumatol\/gu1ac8","article-title":"Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome","volume":"131","author":"Boleto","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2022.103168_bb0080","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2022.103168_bb0085","first-page":"5293981","volume":"2019","author":"Fujita","year":"2019","journal-title":"Case Rep Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103168_bb0090","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/03009742.2017.1387673","article-title":"Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis","volume":"47","author":"Komai","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103168_bb0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00296-020-04767-2","article-title":"Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review","volume":"41","author":"Kyriakou","year":"2021","journal-title":"Rheumatol Int"},{"issue":"20","key":"10.1016\/j.autrev.2022.103168_bb0100","doi-asserted-by":"crossref","first-page":"E7767","DOI":"10.3390\/ijms21207767","article-title":"Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors","volume":"21","author":"Pin","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2022.103168_bb0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-857X(03)00023-1","article-title":"Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being","volume":"29","author":"Medsger","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"10.1016\/j.autrev.2022.103168_bb0110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.autrev.2022.103168_bb0115","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"issue":"10093","key":"10.1016\/j.autrev.2022.103168_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"25","key":"10.1016\/j.autrev.2022.103168_bb0125","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2022.103168_bb0130","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:24:39Z","timestamp":1761600279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1568997222001380"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103168","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors and systemic sclerosis: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103168"}}